10-QT: Protagenic Therapeutics Q1 2026: Merger, Restructuring, Nasdaq Challenges

Protagenic Therapeutics reports a significant net loss in Q1 2026 following a reverse merger, announces a major restructuring, and faces ongoing Nasdaq compliance issues.

Summary

• Protagenic Therapeutics completed a reverse merger with Phytanix Bio, Inc. on May 15, 2025, with Phytanix Bio being the accounting acquirer, bringing five preclinical drug candidates and new employees into the company.
• The company reported a net loss of $5,057,523 for the three months ended June 30, 2025, a substantial increase from $324,355 for the same period in 2024.
• Operating expenses significantly increased to $2,344,412 for the three months ended June 30, 2025, compared to $321,831 in the prior year, driven by higher research and development, general and administrative expenses, and a $1,136,038 write-off of receivables.
• A focused restructuring plan was approved on August 8, 2025, to transition to a virtual operating model, concentrate capital on the PT00114 clinical program, and temporarily suspend preclinical programs, aiming to reduce annualized operating expenses by approximately $8 million.
• The company's cash balance increased to $4,096,189 as of June 30, 2025, from $14,531 on March 31, 2025, primarily due to $3,949,730 from warrant exercises and $395,474 from common stock sales.
• Protagenic Therapeutics continues to face substantial doubt about its ability to continue as a going concern, with a working capital deficit of $6,131,218 and an accumulated deficit of $10,455,129 as of June 30, 2025.
• The company regained compliance with Nasdaq listing rules by June 17, 2025, following a 1-for-14 reverse stock split on May 5, 2025, but is subject to a one-year Mandatory Panel Monitor and received a new delisting notice on August 20, 2025, for late filing of this 10-QT report.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to a significant increase in net loss, worsening working capital deficit, explicit 'going concern' doubt, management terminations, pausing of preclinical programs, and ongoing Nasdaq delisting threats. While a cash infusion occurred, it is insufficient to resolve the underlying financial distress and operational challenges.

Positives

• Cash in bank significantly increased to $4,096,189 as of June 30, 2025, from $14,531 on March 31, 2025, providing immediate liquidity.
• The reverse merger with Phytanix Bio, Inc. expanded the company's product pipeline with five preclinical drug candidate assets (PHYX-001 to PHYX-005) across multiple therapeutic areas.
• The company successfully regained compliance with several Nasdaq listing rules (Bid Price, Public Float, Equity, and Annual Shareholder Meeting Rule) by June 17, 2025, following a reverse stock split and capital raising efforts.
• The approved restructuring plan is expected to reduce annualized operating expenses by approximately $8 million, aiming to conserve cash and focus on high-priority clinical programs.

Negatives

• Reported a significant net loss of $5,057,523 for the three months ended June 30, 2025, compared to $324,355 for the same period in 2024.
• The working capital deficit worsened to $6,131,218 as of June 30, 2025, from $4,952,959 on March 31, 2025.
• The accumulated deficit increased to $10,455,129 as of June 30, 2025, indicating substantial historical losses.
• Substantial doubt exists about the company's ability to continue as a going concern, with current cash resources projected to fund operations only until approximately the end of Q2 FY2027 (September 30, 2026).
• Management terminated the employment of Barrett Evans (CEO & President) and Colin Stott (COO) on August 8, 2025, as part of the restructuring.
• All preclinical programs (PHYX-001 to PHYX-005) acquired through the Phytanix Bio merger have been temporarily suspended, with strategic alternatives being evaluated.
• The company received a new Nasdaq delisting notice on August 20, 2025, for failure to timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025.
• Identified material weaknesses in internal control over financial reporting, including insufficient segregation of duties and limited multiple reviews.
• The company is not forecasting recovery of $643,253 owed by Axiom Real-Time Metrics Inc., which was placed into receivership.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses, accumulated deficit, and negative operating cash flows.
• Risk of delisting from Nasdaq due to failure to timely file the 10-QT report, despite previous compliance efforts.
• Inability to raise additional capital on favorable terms or at all, which would force the company to curtail development efforts.
• Uncertainty regarding the success and timing of clinical trials for PT00114 and the ability to obtain FDA approval, with no revenue anticipated before 2027.
• Reliance on third-party contract research organizations (CROs) and peptide synthesizer companies for drug development, which introduces operational risks.
• Material weaknesses in internal control over financial reporting, increasing the risk of material misstatements.
• Inability to recover funds from Axiom Real-Time Metrics Inc. due to its receivership, impacting cash reserves.
• Risks associated with early-stage preclinical drug development, including the high failure rate and the need for significant future funding for paused programs.
• Potential for one-time charges related to the restructuring plan, which are not yet estimable.

Future Outlook

The company anticipates continued significant expenses and operating losses for the foreseeable future, with no revenue from product sales expected before 2027, even if FDA approval is obtained. Current cash resources are projected to fund operations until approximately the end of the second quarter of fiscal year 2027 (September 30, 2026). The company plans to complete the multiple dose portion of the Phase I study for PT00114 and release results by Q2 FY2026 (September 30, 2025), and initiate a Phase IIa study for PT00114 by Q4 FY2026 (March 31, 2026). The company will need to raise additional capital beyond its current runway and is evaluating strategic alternatives for its paused preclinical programs.

Management Comments

• Management believes that a disciplined cost structure and a sharper focus on near-term value inflection are in the best interests of the Company and its stockholders, leading to the restructuring plan.
• Management intends to implement enhanced controls and procedures to address identified material weaknesses in internal control over financial reporting, despite remaining a small company with limited segregation of duties.

Industry Context

The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. Protagenic Therapeutics operates in several competitive therapeutic areas, including neuropsychiatric and mood disorders, epilepsy, and obesity. The company's focus on cannabinoid-based and novel non-cannabinoid APIs aligns with growing interest in these areas, but also faces intense competition from established pharmaceutical companies and other biotech firms. The obesity market, in particular, is experiencing rapid growth with blockbuster therapies like tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) setting high benchmarks for efficacy and market penetration.

Comparison to Industry Standards

• PHYX-001, a Kv7.2/7.3 agonist for epilepsy and mood disorders, shares the same mechanism of action as compounds like BVH-7000 and XEN1101 (Azetukalner), which are currently in Phase 3 clinical trials for focal onset seizures (FOS), generalized tonic-clonic seizures (GTCS), and major depressive disorder (MDD). XEN1101 has shown encouraging efficacy and safety in Phase 2 studies.
• PHYX-002, a cannabinoid asset, aims to develop a product with improved potency and lower dosing requirements compared to currently available cannabinoid medicines, such as Epidiolex.
• PHYX-003, an anti-obesity candidate, is designed to potentially enhance weight-loss outcomes compared with current blockbuster therapies like tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy).

Management Changes

Corporate Governance

Legal Proceedings

• The company filed a complaint in the central district of California against its former contract research organization, Axiom Real-Time Metrics Inc., seeking $643,253 for pre-paid clinical study work that Axiom failed to undertake.
• Axiom Real-Time Metrics Inc. was placed into receivership on July 11, 2025, and its assets were sold, significantly reducing the chance of the company recovering any funds from Axiom.

Related Party Transactions

• Loans payable to related parties totaled $856,957 as of June 30, 2025, up from $779,201 on March 31, 2025. These advances are non-interest bearing and have no specified repayment terms.
• The company is provided free office space by its Executive Chairman, Dr. Garo H. Armen, for quarterly board meetings and annual shareholder meetings.
• During the year ended December 31, 2021, the company engaged Agenus Inc., a related party (due to shared Chairman), for research and development services, but no expenses or outstanding amounts were incurred for the three months ended June 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from future capital raises and warrant exercises, as well as the risk of Nasdaq delisting and the substantial doubt about the company's going concern status.
• Employees, particularly those associated with preclinical activities, are impacted by headcount reductions as part of the restructuring plan.
• Creditors face increased risk due to the company's worsening working capital deficit and going concern issues.
• Customers (potential future patients) may experience delays or changes in the development of new therapeutics due to the pausing of preclinical programs and the focused clinical strategy.

Next Steps

• Complete the multiple dose portion of the Phase I study for PT00114 by Q2 FY2026 (September 30, 2025).
• Make public the results from the multiple dose portion of the Phase I study for PT00114 by Q2 FY2026 (September 30, 2025).
• Initiate a Phase IIa study for PT00114 by Q4 FY2026 (March 31, 2026).
• Evaluate strategic alternatives, including partnerships and/or out-licensing, for the temporarily suspended preclinical programs (PHYX-001 to PHYX-005).
• Implement controls and procedures to remediate identified material weaknesses in internal control over financial reporting.
• Submit a plan to Nasdaq to regain compliance for the late 10-QT filing and/or file the Form 10-Q within the 60-day period granted by Nasdaq.
• Seek additional debt or equity financing to fund operations beyond the current cash runway (projected to end Q2 FY2027).

Key Dates

Recommendation

Protagenic Therapeutics faces severe financial distress, evidenced by a substantial increase in net loss, a worsening working capital deficit, and explicit 'going concern' doubt with a limited cash runway. The company is undergoing a significant restructuring, including management changes and the suspension of preclinical programs, which introduces considerable operational uncertainty. Furthermore, the company received a new Nasdaq delisting notice for late filing, indicating ongoing regulatory compliance issues. While a recent capital raise provided some liquidity, it is insufficient to address the fundamental financial and operational challenges. The high-risk profile, coupled with the lack of near-term revenue and the pausing of promising pipeline assets, makes this a highly speculative investment with significant downside potential.

Keywords

Biopharmaceutical, Neuropsychiatric disorders, Mood disorders, Drug development, Clinical trials, SEC filing, Nasdaq compliance, Reverse merger, Restructuring, Going concern, PT00114, Cannabinoid therapeutics, Obesity drug, Epilepsy, Bladder pain syndrome, Stilbenoid, Intellectual property